A Peek Into Today’s Volatile Biotech Stocks
Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM
At the 14th International Symposium on MPS and Related Diseases, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) presented positive pivotal Phase 3 trial of recombinant human …
In a research report issued Friday, Canaccord analyst Arlinda Lee reiterated a Buy rating on shares of Ultragenyx Pharmaceutical Inc (NASDA:RARE) with a price …
Analyst Steven Breazzano initiated an Overweight rating for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) with a price target of $70, marking an increase of 35% from …